According to a report by Endiya Partners, India’s bioeconomy is projected to grow from $10 billion in 2014 to about $195 billion by 2026 and nearly $300 billion by 2033, fueled by a massive global patent cliff, faster clinical trials, and supportive government initiatives.
Glimpse:
The report titled “India’s Biopharma Moment: Perspectives from DEMO Biotech” positions India as an emerging cost effective hub for biopharma innovation. It highlights India’s advantages in generics and vaccines, faster patient recruitment, and recent regulatory reforms in March 2026 that are expected to shorten drug development timelines.
India’s biotech sector is on the verge of a major transformation, with its bioeconomy expected to rise sharply from $10 billion in 2014 to approximately $195 billion by 2026, and nearly $300 billion by 2033, as per a report from Endiya Partners.
The report, “India’s Biopharma Moment: Perspectives from DEMO Biotech,” points to a significant opportunity created by a global patent cliff worth around $300 billion approaching by 2030. This situation, along with rising drug development costs averaging $2.2 billion per asset and timelines stretching to nearly 100 months, makes India an attractive destination for biopharma activities.
India is gradually moving from being a global leader in generics to a high velocity, cost effective hub for biopharma innovation. The country already supplies about 20% of the world’s generic medicines and over 60% of vaccines. It also offers a clear advantage through faster patient enrollment up to ten times quicker and enables three to four times more drug development attempts for every dollar invested
Government support is playing a vital role in this progress. Important steps include the ₹10,000 crore Biopharma Shakti scheme and the ₹1 lakh crore Research, Development, and Innovation (RDI) fund. In addition, revisions to the New Drugs and Clinical Trials Rules in March 2026 have introduced a streamlined 45-day approval process and prior intimation pathways, which are likely to cut development cycles by 90 to 120 days.
India’s biotech ecosystem has also expanded significantly and now includes over 2,500 startups, around 100 incubators, more than 600 research institutes, and 200 accredited laboratories. While these developments show growing global confidence in Indian innovation, the report notes some remaining challenges such as limited pilot scale GMP infrastructure, late stage funding issues, talent shortages, and gaps in translational research. To sustain this momentum, it recommends four key priorities: blended financing models, stronger industrial intelligence, better translational infrastructure, and a more flexible regulatory environment.
“India is transitioning from a global leader in generics to a high velocity, cost effective hub for biopharma innovation.”
By
HB Team
Related News
